导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.64% | 3145/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.71% | 2673/5421 |
| 近一季 | -8.86% | 2993/5209 |
| 近半年 | -5.26% | 2803/4920 |
| 近一年 | -1.95% | 2949/4366 |
| 近两年 | 41.90% | 1798/2954 |
| 近三年 | 30.90% | 1019/2253 |
| 成立以来 | 83.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.79% 2909/4961 |
11.67% 2308/5312 |
- - |
- - |
| 2025 | 18.61% 2298/4813 |
1.14% 1692/3635 |
2.57% 1486/4076 |
14.63% 2889/4524 |
-0.25% 2442/4813 |
| 2024 | 22.08% 394/3463 |
5.13% 401/2808 |
0.42% 615/3014 |
15.71% 1647/3129 |
-0.06% 1303/3463 |
| 2023 | -7.97% 968/2656 |
4.62% 908/2280 |
-4.45% 1174/2385 |
-2.20% 636/2515 |
-5.87% 1533/2655 |
| 2022 | -19.83% 905/2207 |
-15.26% 1030/1919 |
8.61% 348/2016 |
-13.15% 845/2113 |
0.29% 1514/2208 |
| 2021 | 4.39% 581/1822 |
-1.38% 480/1255 |
7.10% 700/1330 |
-3.24% 622/1466 |
2.13% 689/1822 |
| 2020 | 35.38% 417/1250 |
-9.05% 652/1028 |
14.08% 572/1067 |
14.97% 247/1164 |
13.48% 357/1184 |
| 2019 | 13.89% 703/1092 |
4.45% 732/739 |
4.96% 17/788 |
0.64% 495/850 |
3.23% 842/918 |
| 2018 | 0.48% 57/834 |
- - |
1.25% 25/631 |
-0.09% 169/660 |
-0.57% 4/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 海富通沪深300指数增强C VS. 长安沪深300非周期A(740101) |